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Background: BCG is a prototypal cancer immunotherapeutic factor currently approved of bladder cancer. In
attempt to further enhance the effectiveness of immunotherapy of bladder cancer and, potentially, other
malignancies, we evaluated the impact of BCG on local production of chemokines attracting the desirable effector
CD8+ T cells (CTLs) and undesirable myeloid-derived suppressor cell (MDSCs) and regulatory T(reg) cells, and the
ability of bladder cancer tissues to attract CTLs.
Methods: Freshly resected bladder cancer tissues were either analyzed immediately or cultured ex vivo in the
absence or presence of the tested factors. The expression of chemokine genes, secretion of chemokines and their
local sources in freshly harvested and ex vivo-treated tumor explants were analyzed by quantitative PCR (Taqman),
ELISAs and immunofluorescence/confocal microscopy. Migration of CTLs was evaluated ex vivo, using 24-transwell
plates. Spearman correlation was used for correlative analysis, while paired Students T test or Wilcoxon was used for
statistical analysis of the data.
Results: Bladder cancer tissues spontaneously expressed high levels of the granulocyte/MDSC-attractant CXCL8 and
Treg-attractant CCL22, but only marginal levels of the CTL-attracting chemokines: CCL5, CXCL9 and CXCL10. Baseline
CXCL10 showed strong correlation with local expression of CTL markers. Unexpectedly, BCG selectively induced only
the undesirable chemokines, CCL22 and CXCL8, but had only marginal impact on CXCL10 production. In sharp
contrast, the combination of IFNα and a TLR3 ligand, poly-I:C (but not the combinations of BCG with IFNα or BCG
with poly-I:C), induced high levels of intra-tumoral production of CXCL10 and promoted CTL attraction. The
combination of BCG with IFNα + poly-I:C regimen did not show additional advantage.
Conclusions: The current data indicate that suboptimal ability of BCG to reprogram cancer-associated chemokine
environment may be a factor limiting its therapeutic activity. Our observations that the combination of BCG with
(or replacement by) IFNα and poly-I:C allows to reprogram bladder cancer tissues for enhanced CTL entry may
provide for new methods of improving the effectiveness of immunotherapy of bladder cancer, helping to extend
BCG applications to its more advanced forms, and, potentially, other diseases.
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Bladder cancer, originating from the transitional cells of
the bladder urothelium, accounts for an estimated
72,570 new cases and 15,210 deaths in the US. Though
bladder cancer is highly treatable if found early, it
becomes increasingly difficult to treat at later stages.
Intravesicular BCG administration has been the stan-
dard therapy for treatment of bladder cancer, but its
effectiveness is limited only to superficial bladder
cancers [1-4].
Tumor infiltration with effector CD8+ T cells (CTL)
has been associated with good prognosis in various can-
cers [5-18], therefore immunotherapies able of enhan-
cing intra-tumoral CTL levels may be also effective for
invasive bladder cancers. Previous studies by us [19] and
others [10,20-25] have shown that intra-tumoral expres-
sion of chemokines regulate local levels of CTL infiltra-
tion, suggesting that T cell-targeting immunotherapies
can benefit from modulating tumor-associated chemo-
kine microenvironments in order to enhance local CTL
infiltration.
Since myeloid-derived suppressor cell (MDSCs) and
regulatory T(reg) cells are both known to protect tumors
from CTL-mediated elimination and to promote tumor
growth, ideal immunotherapies should be able to se-
lectively enhance tumor production of CTL-attracting
chemokines, without enhancing local levels of CXCL8,
CXCL12 and CCL22, the chemokines mediating local
attraction of MDSC and Treg to tumors [26-30]. Prom-
pted by the above considerations, we evaluated the
ability of BCG and alternative adjuvants to reprogram
local chemokine milieu in bladder cancer to enhance
the overall magnitude of local production of CTL-
attracting chemokines in relation to MDSC/Treg-attrac-
tants. Unexpectedly, we observed that BCG, used alone,
not only failed to enhance local expression of CTL-
attracting chemokines, CCL5 and CXCL10, but selec-
tively enhanced MDSC- and Treg-attracting chemokines,
CCL22 and CXCL8. These undesirable side-effects
could be reversed by the combination of IFNα and poly-
I:C (TLR3 ligand), raising the possibility of enhancing
the effectiveness of the BCG-based and other forms of
immunotherapy of bladder cancer and potentially other
malignancies.
Results
Bladder cancer tissues spontaneously produce MDSC- and
Treg-attracting CXCL8 and CCL22, but not effector
T cell-attracting chemokines
In order to evaluate the spontaneous chemokine ex-
pression and determine the baseline chemokine pro-
duction pattern in bladder tumors, we isolated RNA
from resected tumors of bladder cancer patients
(N = 20) and performed real-time PCR (Taqman)analysis for the chemokines previously implicated in
CTL or MDSC/Treg attraction to tumor lesions [26-30].
We observed that bladder tumors uniformly expressed
only low levels of CTL attracting chemokines: CCL5,
CXCL9, and CXCL10 (respective ligands for CTL-
expressed CCR5 and CXCR3 [19]). In a striking contrast
to the above CTL-attractants, the chemokines implicated
in attracting MDSCs and Tregs, CCL2 (MCP-1), CCL22
(MDC) and CXCL8 (IL-8) were highly expressed chemo-
kines (Figure 1A), with CXCL8 uniformly expressed at the
highest levels. The prevalence of high CCL22 and CXCL8
in bladder tumors at baseline is consistent with previous
studies [31-33] which showed the abundance of these
undesirable chemokines, particularly in patients with poor
prognosis. High intra-tumoral expression of CXCL8
was confirmed by confocal analysis of tumor samples
(Figure 1C). Taqman analysis for different markers of im-
mune infiltrate (Figure 1B), using primers for CD4, CD8,
GZMB and T-bet (effector cell markers), CD33 (myeloid
marker), GITR (Treg marker) and NCF2 (myeloid or
neutrophil marker) revealed that NCF2 expression was do-
minant, corresponding to the high IL-8 levels (see below).Intra-tumoral expression of CCL5, CXCL9, and CXCL10
shows a strong correlation with CTL markers CD8 and
Granzyme B
In order to test if the spontaneous expressed nominal
CTL-attracting chemokines indeed predict local CTL
infiltration in bladder cancer tissues, we attempted to
correlate intra-tumoral mRNA expression of CCR5
ligands and CXCR3 ligand (CCL5, CXCL9 and CXCL10)
with Intra-tumoral mRNA expression of CTL markers.
As shown in Figure 2, Spearman correlative analysis of
the chemokines and CTL markers revealed strong cor-
relation between CD8 and Granzyme B with CCL5,
CXCL9 and CXCL10. As expected, neither of these
markers was correlated with the local expression of
a Treg-attractant, CCL22 (data not shown). The levels
of IL-8 expression were strongly correlated with
NCF2 expression (neutrophil marker; Additional file 1:
Figure S1).BCG treatment of bladder tumors up regulates CXCL8,
CCL22 expression, but not CXCL10
Using CXCL10 as a representative of CTL-attracting
chemokines, involved in attraction of CXCR3+ CTL im-
plicated with good prognosis for cancer patients
[7,11,12,15], we tested whether BCG treatment can en-
hance intra-tumoral production CXCL10. Unexpect-
edly, we observed that, while BCG strongly up regulated
the secretion of CXCL8 (P < 0.05) and CCL22 (P < 0.05)
by ex vivo-treated bladder cancer explants (n = 11 pa-
tients), it did not enhance CXCL10 secretion (Figure 3).
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Figure 1 Bladder cancer tissues spontaneously express high levels of MDSC/Treg- attracting chemokines CCL22 and CXCL8, but only
marginal levels of CTL- attractants, CCL5, CXCL9 and CXCL10. A. Spontaneous chemokine mRNA expression by bladder tumors (N = 20
different patients) by real-time PCR analysis (Taqman). B. Spontaneous mRNA expression analysis for markers of immune filtrate in bladder tumors
(N = 20 different patients) by real-time PCR analysis (Taqman). The levels of chemokine and immune filtrate markers were normalized to HPRT1
mRNA (housekeeping gene). C. Confocal analysis for CXCL8 (Red), CXCL10 (Green) protein expression in 2 representative bladder tumors. Nuclei
were stained with Sytox orange (Blue) and specificity controls (secondary antibody only) are shown in insets.
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enhancement of undesirable chemokines
Since we have previously demonstrated that the combi-
nation of IFNα with poly-I:C effectively up regulatedCTL chemokines in colorectal cancer tissues [19], we
tested whether their addition to BCG can enhance its
effectiveness. In a preliminary set of experiments we
used an in vitro model system involving TS4 bladder
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Figure 2 CCR5- and CXCR3-binding chemokines (CCL5, CXCL9 and CXCL10) show high correlation with CTL markers in bladder cancer
tissues. Spearman (Rho) analysis of the correlations between the spontaneous expression (mRNA) of CTL markers (CD8 and Granzyme B) and CTL
attracting chemokines (CCL5, CXCL9 and CXCL10). Values on the scale are log10 transformations of relative mRNA levels for each of the markers
were evaluated using real time PCR (Taqman).
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(Additional file 1: Figure S3) to directly compare mul-
tiple combinatorial adjuvants in a single experiment,
without the limitation imposed by the amount of blad-
der cancer tissues available from resections and their
variability between different patients. In accordance with
the data from our bladder cancer explant cultures, BCG
alone was completely ineffective in promoting CXCL10
secretion in such cell cultures. In contrast, we observed
strong synergy between IFNα and poly-I:C in promoting
CXCL10 secretion, both in the absence and in the pres-
ence of BCG (Additional file 1: Figure S3). Importantly,
neither the combination of BCG with poly-I:C nor the
combination of BCG with IFNα was effective, which
may explain the limited effectiveness of that later com-
bination in the recently-completed clinical trial [4,34,35].In accordance with these observations, our experi-
ments performed in the tumor tissue explant model
(n = 6 patients), demonstrated that in contrast to BCG,
the combination of IFNα and poly-I:C strongly elevated
tumor secretion of CXCL10. The combination of BCG
with IFNα + poly-I:C resulted in only marginal or no fur-
ther enhancement of CXCL10 secretion, but was asso-
ciated with the undesirable elevation of CCL22 (Figure 4).
IFNα + poly-I:C-treated tumors show enhanced attraction
of effector CD8+ cells
To test whether the modified chemokine production
patterns in BCG- and IFNα + poly-I:C-treated bladder
cancer tissues result in their differential ability to attract
CTLs, supernatants of the differentially-treated bladder
cancer tissues were tested for their ability to attract
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Figure 3 BCG exposure of bladder tissues does not induce
CXCL10, but further enhances tumor production of MDSC/Treg-
attracting CCL22 and CXCL8. Bladder tumor biopsies were
cultured in the absence or presence of BCG (2 × 106 CFU) for
24 hours. CXCL10, CCL22 and CXCL8 proteins in tumor supernatants
were measured by ELISA and expressed as ng/ml. The results were
evaluated using two- tailed, paired Student’s t test. Statistically
significant differences between groups are highlighted by * (P < 0.05).
NS-Not significant.
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Figure 4 Combination of IFNα with poly-I:C is a powerful
inducer of CXCL10 in bladder cancer lesions in the absence or
presence of BCG. Bladder tumors biopsies were cultured for
24 hours in the absence or presence of 10,000 units IFNα + 20 μg/ml
specific poly-I:C, with or without BCG (2 × 106 CFU). The levels of
CXCL10 and CCL22 in tumor supernatants were measured by specific
ELISAs. The results were evaluated using two- tailed, paired Wilcoxon
Test. Statistically significant differences between groups are highlighted
by * (P < 0.05).
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SEB-loaded LPS + IFNγ matured DCs, capable of high
IL-12 production [36,37]). As expected, bladder cancer
tissues (n = 3 patients) treated with IFNα + poly-I:C
significantly attracted more of the effector CD8+ T cells
than untreated or BCG alone treated tumors (Figure 5).
The combination of BCG with IFNα + poly-I:C didn’t
further increase the CTL attraction. These data indicate
that BCG by itself is insufficient to reprogram the
bladder cancer-associated chemokine environment for
enhanced CTL attraction, but that such goal can be
achieved by the combination of BCG with (or its re-
placement by) IFNα plus poly-I:C.
Discussion
BCG is a prototypal cancer immunotherapeutic factor
which has been widely demonstrated to be effective in
the treatment of superficial bladder cancer [1-4]. In
attempt to further enhance the effectiveness of the
immunotherapy of bladder cancer, including its more
advanced stages, and potentially other malignancies, we
evaluated the impact of BCG on local production of the
chemokines attracting the desirable effector CD8+ T cells
and undesirable MDSCs and Treg cells.
We observed that bladder cancer tissues spontaneously
expressed high levels of Treg- and MDSC- recruitingN=3
(-
)
B
C
G
IF
N
+ p
o l
y -
I :C
B
C
G
+
0
1 0 0
2 0 0
3 0 0
B la d d e r tum o rs tre a te
M
ig
ra
te
d
C
D
8
+
G
Z
M
B
+
T
c
e
ll
s
**
*
*
*
Figure 5 Bladder cancer lesions exposed to IFNα + poly-I:C or BCG + I
Day 6 effector Granzyme B+/CD8+ T cells (induced by SEB-loaded LPS + IFN
2 hours towards the supernatants from the differentially-treated bladder ca
chamber were harvested and stained for CD8, Granzyme B. The counts of G
evaluated using two- tailed, paired Student’s t test. Statistically significant diffechemokines (CCL2, CCL22 and CXCL8, respective li-
gands for CCR2, CCR4 and CXCR1/2), but only low levels
of CTL- attracting chemokines (CCL5, CXCL9-10; re-
spective ligands for CCR5 and CXCR3), suggesting that
the chemokine imbalance can contribute to the pathogen-
esis of bladder cancer and may limit the effectiveness of
its immunotherapies. Unexpectedly, despite the docu-
mented beneficial role of BCG in bladder cancer, our data
indicate that its ability to modify the microenvironment of
bladder cancer ex vivo is largely limited to the enhance-
ment of local production of Treg- and MDSC-attracting
chemokines, CCL22 and CXCL8, without inducing
CXCL10 or facilitating CTL attraction. Our current data
is consistent with the previous observations that bladder
cancer tissues do not produce the desirable chemokine
CXCL10 within the first week of BCG treatment, although
can produce this factor after 3 weekly doses of BCG [38].
They are also consistent with the previous observations
that bladder cancer lesions typically produce high levels of
CCL22 and CXCL8 at baseline [31-33,39,40], which may
be further amplified by treatment of patients with BCG
and particularly by treatment with by BCG combined with
chemotherapy [32], constituting the undesirable side-
effect of treatment [33]. Since intratumoral expression of
CXCL8 has been shown to be a negative prognostic
marker [31], these observations highlight a potential forIF
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FNα + poly-I:C show strongly-enhanced CTL-attracting activity.
γ-matured DC [36,37]) were harvested and allowed to migrate for
ncer tissues in 24 trans-well system. Migrated cells in the bottom
ranzyme B+ CD8+ T cells were analyzed by FACS. The results were
rences between groups are highlighted by * (P < 0.05) or ** (P < 0.01).
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environments to improve the outcomes of BCG-treatment
and chemotherapy of this cancer type.
This selective activity of BCG may result from its
dominant pattern of TLR2-mediated signaling [41],
which has been shown to induce significantly less type-1
interferons compared to other TLR ligands [42,43]. In
accordance with this possibility, our observations sug-
gests that the combination of IFNα with poly-I:C
(a TLR3 ligand) or BCG + IFNα + poly-I:C (although nei-
ther BCG + IFNα nor BCG + poly-I:C) are highly effect-
ive in enhancing intra-tumoral production of CXCL10 in
bladder cancer tissues and promoting CTL infiltration.
Interestingly, both these effective combinations showed
at least partial selectivity in inducing CXCL10 (rather
than CCL22) in cancer tissues. Our current experiments
aim to determine if the additional inclusion of COX in-
hibitors (which proved to be effective in suppressing
local production of CCL22 in metastatic colon cancer le-
sions [19]) with the currently-evaluated BCG + IFNα +
poly-I:C combination will further potentiate its effective-
ness by suppressing COX-2 dependent production of
CCL22, CXCL8 and boosting induction of CXCL10 and
other CTL-attracting factors.
Conclusion
Our current data suggest that the suboptimal ability of
BCG to reprogram cancer-associated chemokine environ-
ments may represent a factor limiting its clinical activity,
especially in more advanced stages of bladder cancer, and
may represent an area of additional therapeutic interven-
tion. Our identification of the combination of IFNα and
poly-I:C, as factors which may supplement (or replace)Table 1 Bladder cancer patients
Patient number N (%)
Total qPCR ana
Patients 23(100) 20(100)
Male 15(65) 14(70)
Female 8(35) 6(30)
Tumor stage:
Stage 0 4(17) 4(20)
Stage 0is 1(4) 1(5)
Stage 1 6(26) 5(25)
Stage 2 2(9) 2(10)
Stage 3 8(35) 6(30)
Stage 4 2(9) 2(10)
Prior treatment:
None 15(65) 13(65)
BCG 5(22) 5(25)
Other treatment 3(13) 2(10)BCG in effective reprogramming of cancer tissues for en-
hanced CTL entry, may help to improve the effectiveness
of immunotherapy of bladder cancer and enhance the ap-
plications of BCG to its more advanced forms, as well as
other malignancies or other disease states (such a myco-
bacterial infections), where the current BCG-based thera-
peutic regimens are not effective.
Methods
Ex vivo culture of bladder tumor explant tissues
Tumor from patients was obtained by informed consent
under the IRB approved protocol UPCI 86–022. Patient
clinical characteristics and sets of patients used for spe-
cific types of experiments are given in Table 1 below.
Using a 2 mm biopsy punch knife, uniform 2 mm
cubes of resected tumor tissue were made. Tumor ex-
plants were assorted as 3 × two mm cubes/wells in 48
well plate respectively and cultured in IMDM plus 10%
FBS, either untreated or treated with 2 × 106 CFU of
BCG (TICE® BCG, Schering Plough, NJ) and/or 10,000
units of IFNα (Merck, NJ), 20 μg/ml of poly-I:C (Sigma
Aldrich, St. Louis, MO). Tumor tissue biopsies were
harvested at 0 and 24 hours for mRNA and confocal
microscopy analysis and culture supernatants were har-
vested at 24 hours for ELISA.
Bladder cancer cell line-macrophage-fibroblast co-culture
system
In order to compare multiple combinatorial adjuvants in
a single experiment, we established a model system in-
volving 1 × 105 each of TS4 (bladder cell line; ATCC,
Manassas, VA), blood isolated monocytes (isolated by
CD14 microbeads; Miltenyi Biotech.) and fibroblastslysis ELISA analysis Chemotaxis
11(100) 3(100)
6(55) 1(33)
5(45) 2(67)
2(18)
3(27) 1(33)
1(9)
4(36) 2(67)
1(9)
7(64) 2(67)
2(18)
2(18) 1(33)
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The cells were treated with the indicated permutation
combinations of celecoxib (10 μM, Biovision, Milpitas,
CA), IFNα (10000 units/ml), poly-I:C (20 μg/ml) and
BCG (2 × 106 CFU) for 24 hours and supernatants were
harvested for ELISA analysis of various chemokines. In
preliminary experiments, we used macrophages gene-
rated from healthy donors’ monocytes in 6 day-long
GM-CSF-supplemented cultures, to directly compare
the chemokine-modulating impact of increasing doses of
BCG in the same experiment. As shown in Additional
file 1: Figure S2, different doses of BCG (0.4, 2 and
10 × 106 CFU), all induced high levels of CXCL8, but not
CXCL10.
Taqman analysis of mRNA expression in tumor
Tumor biopsies were placed into lysing Matrix E tubes
(MP Biologicals, Solon, OH), containing RLT buffer
(RNAeasy kit, Qiagen, Valencia, CA), agitated in FP120
homogenizer (MP Biologicals). Debris-free supernatants
from the lysis matrix tubes were transferred into new
tubes and total RNA was extracted using the RNAeasy
kit (Qiagen,MA). 1 μg of RNA extracted by above
method was used for cDNA synthesis using Quanta bio-
sciences synthesis kit and 25–50 ng of the resulting
cDNA was used to do mRNA expression analysis by
Taqman, using primers and equipment (Step One Plus
system) from (Life Technologies, Long Island, NY).
Confocal microscopy analysis of tumor sections
Tumor biopsies were embedded in OCT medium con-
taining cryomolds and immediately frozen in 2-methyl-
butane. 5 μm frozen sections of the tissues were made
using the cryostat and layered on superfrost® plus slides
(Thermo Scientific, Rockford, IL). The slides were fixed
in 4% para-formaldehyde for 15 minutes, washed and
blocked for 60 minutes at room temperature. The slides
were then stained for 3 hours at room temperature (RT)
with antibodies for CXCL10 (ab9807) and CXCL8
(ab18672), both from Abcam, Cambridge, MA. The
slides were washed 5 times with 1 × PBS and incubated
with secondary antibodies anti-rabbit-Alexa 488, anti-
mouse-Alexa 647 (both from Cell Signal, Danvers, MA)
and with nuclear dye Sytox orange (Invitrogen, Carlsbad,
CA) for 30 minutes at RT. The slides were washed 5
times with 1 × PBS. Cover slips were mounted on the
sections using prolong gold anti-fade solution (Life
Technologies). Confocal analyses of stained slides were
performed using a LEICA TCS SL DMRE Microsystems.
ELISA analysis of chemokines in tumor ex vivo culture or
in cell co-cultures
24 hour culture supernatants from tumor ex vivo culture
were analyzed by ELISA for chemokine proteins expressed.ELISA primary and secondary antibody pairs for the ana-
lysis of CCL5, CXCL8 and CXCL10, protein secretion were
purchased from Peprotech, Rocky Hill, NJ. ELISA plates
(Corning Inc, Corning, NY) were coated overnight at RT
with 100 μL of primary antibody at 1 μg/mL, followed by
washing and blocking with PBS + 4% BSA for 1 hour.
50 μL of samples were added to the wells and incubated
for 1 hr and subsequently washed and incubated with
50 μL of biotinylated secondary antibodies at 0.5 μg/mL
for 1 hour. The plates were washed and incubated
for 30 minutes with streptavidin-HRP conjugate (Pierce
Biotechnology Inc, Rockford, IL), diluted 1:10000 in wash
buffer (50 mM Tris, 0.2% Tween). The plates were washed
and detected with 50 μL of TMB substrate (Pierce).
Reactions were stopped with 2% H2SO4 and 450 nm ab-
sorbance was measured, using Wallac 1420 Victor 2 mi-
croplate Reader (Perkin Elmer, Waltham, MA).
Generation of effector T cells
Naïve CD8+ T cells were purified from peripheral blood
of normal donor using EasySep naïve CD8 enrichment
kit (#19158, Stemcell Tech, Vancouver, Canada). Isolated
naïve CD8+ T cells were stimulated with SEB (1 ng/ml)
pulsed, LPS + IFNγ-matured DC for 6 days [36]. On 6th
day, effector CD8+ T cells were harvested, cells counted,
density-adjusted to 106 cells per ml and used in chemo-
taxis assays.
Chemotaxis
In a 24 trans-well plates with membrane with 5 μM pore
size (#3421, Corning, CA), 2 × 105 (200ul) effector CD8+
T cells were loaded onto top chambers and allowed to
migrate for 2 hours [19,36,44] towards 400 μl of super-
natants generated from 24 hour bladder cancer explant
cultures. Migrated cells were harvested from the bottom
chambers and stained for CD8 and Granzyme B (GZMB).
Number of migrated GZMB positive effector CD8+ T cells
were quantified by fixed 100 μl run on Accuri C6 (BD
Biosciences, San Jose, CA).
Statistical analysis
Spearman rank correlations (rho) between the mRNA of
chemokine genes and cytotoxic T cell markers were
calculated. Comparisons of continuous variables between
groups were performed by 2 tailed, paired t test or
paired Wilcoxon test using graphPad Prism 6 software.
The values of P <0.05 were considered as significant.
Additional file
Additional file 1: Figure S1. Intratumoral CXCL8 expression shows
strong correlation with the neutrophil marker, NCF2. Spearman (rho)
analysis of the correlation between intra-tumoral mRNA expression of
CXCL8 (IL-8) with Intra-tumoral expression of NCF2 (Neutrophil marker).
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secretion by macrophages. Macrophages, generated by culturing
monocytes in presence of GMCSF for 6 days, were exposed to increasing
doses of BCG (0.4, 2, 10 × 106 CFU) for 24 hrs. Secretion of CXCL8 and
CXCL10 was measured by specific ELISAs. Figure S3. BCG combination
with IFNα + poly-I:C reduces CXCL10 levels in co-cultures of bladder
cancer cells, macrophages and fibroblasts. TS4(Bladder cell line) was co
cultured with macrophages and Fibroblasts in ratio 1:1:1 and treated with
different permutations of celecoxib, IFNα, poly-I:C, and BCG. CXCL10
secretion was measured in 24 hour supernatants by ELISA. CCL22 and
CXCL8 were below detection levels.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RM was involved in concept, design and performing of experiments, and wrote
the manuscript. LW was involved in performing experiments. JP was involved in
performing experiments; JRG participated in the study design, provided patient
material and analyzed patient-related data, and was involved in preparation of
the manuscript. PK conceived the study, was involved in concept and design of
experiments, critically involved in writing and editing of the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This study was supported by the NIH grants P01 CA132714 and P30 CA047904.
Liwen Wang was partially supported by the Tsinghua University – University of
Pittsburgh Joint Education Program and China Scholarship Council.
Author details
1Departments of Sugery, University of Pittsburgh, Pittsburgh, PA 15213, USA.
2Department of Urology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
3Department of Infectious Diseases and Microbiology, University of
Pittsburgh, Pittsburgh, PA 15213, USA. 4Department of Immunology,
University of Pittsburgh, Pittsburgh, PA 15213, USA. 5University of Pittsburgh
Cancer Institute, Pittsburgh, PA 15213, USA. 6Department of Surgery,
University of Pittsburgh, Hillman Cancer Center, UPCI Research Pavilion,
Room 1.46b, 5117 Center Avenue, Pittsburgh, PA 15213, USA.
Received: 24 November 2014 Accepted: 16 February 2015
References
1. Gofrit ON, Pode D, Pizov G, Zorn KC, Katz R, Duvdevani M, et al. The natural
history of bladder carcinoma in situ after initial response to bacillus
Calmette-Guerin immunotherapy. Urol Oncol. 2009;27:258–62.
2. Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer:
an immunotherapy success story. J Urol. 2008;179:53–6.
3. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in
the treatment of superficial bladder tumors. J Urol. 1976;167:891–3.
discussion 893–895.
4. Zhu S, Tang Y, Li K, Shang Z, Jiang N, Nian X, et al. Optimal schedule of
bacillus calmette-guerin for non-muscle-invasive bladder cancer: a
meta-analysis of comparative studies. BMC Cancer. 2013;13:332.
5. Fujii H, Arakawa A, Utsumi D, Sumiyoshi S, Yamamoto Y, Kitoh A et al.
CD8+ tumor-infiltrating lymphocytes at primary sites as a possible prognostic
factor of cutaneous angiosarcoma. Int J Cancer. 2014;134(10):2393–2402.
6. Nasman A, Romanitan M, Nordfors C, Grun N, Johansson H, Hammarstedt L,
et al. Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical
outcome and human papillomavirus (HPV) status in tonsillar cancer.
PLoS One. 2012;7:e38711.
7. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in
human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306.
8. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al.
Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast
cancer. J Clin Oncol. 2011;29:1949–55.
9. Yamada N, Oizumi S, Kikuchi E, Shinagawa N, Konishi-Sakakibara J, Ishimine
A, et al. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in
malignant pleural mesothelioma after resection. Cancer Immunol
Immunother. 2010;59:1543–9.10. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, et al.
Biomolecular network reconstruction identifies T-cell homing factors associated
with survival in colorectal cancer. Gastroenterology. 2010;138:1429–40.
11. Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, et al.
CD8+ enriched “young” tumor infiltrating lymphocytes can mediate
regression of metastatic melanoma. Clin Cancer Res. 2010;16:6122–31.
12. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al.
In situ cytotoxic and memory T cells predict outcome in patients with
early-stage colorectal cancer. J Clin Oncol. 2009;27:5944–51.
13. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, et al. CD8
tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive
urothelial carcinoma. Proc Natl Acad Sci U S A. 2007;104:3967–72.
14. Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der
Hulst JM, Drijfhout JW, et al. High number of intraepithelial CD8+ tumor-
infiltrating lymphocytes is associated with the absence of lymph node
metastases in patients with large early-stage cervical cancer. Cancer Res.
2007;67:354–61.
15. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C,
et al. Type, density, and location of immune cells within human colorectal
tumors predict clinical outcome. Science. 2006;313:1960–4.
16. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial
CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell
ratio are associated with favorable prognosis in ovarian cancer. Proc Natl
Acad Sci U S A. 2005;102:18538–43.
17. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al.
Effector memory T cells, early metastasis, and survival in colorectal cancer.
N Engl J Med. 2005;353:2654–66.
18. Prall F, Duhrkop T, Weirich V, Ostwald C, Lenz P, Nizze H, et al. Prognostic
role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer
with and without microsatellite instability. Hum Pathol. 2004;35:808–16.
19. Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, et al.
NF-kappaB hyperactivation in tumor tissues allows tumor-selective
reprogramming of the chemokine microenvironment to enhance the
recruitment of cytolytic T effector cells. Cancer Res. 2012;72:3735–43.
20. Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H, Mori M. The high
expression of Fractalkine results in a better prognosis for colorectal cancer
patients. Int J Oncol. 2005;26:41–7.
21. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, et al.
Chemokine expression in melanoma metastases associated with CD8+
T-cell recruitment. Cancer Res. 2009;69:3077–85.
22. Ohtani H, Jin Z, Takegawa S, Nakayama T, Yoshie O. Abundant expression of
CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation
of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. J Pathol.
2009;217:21–31.
23. Venetz D, Ponzoni M, Schiraldi M, Ferreri AJ, Bertoni F, Doglioni C, et al.
Perivascular expression of CXCL9 and CXCL12 in primary central nervous
system lymphoma: T-cell infiltration and positioning of malignant B cells.
Int J Cancer. 2010;127:2300–12.
24. Martinet L, Le Guellec S, Filleron T, Lamant L, Meyer N, Rochaix P, et al. High
endothelial venules (HEVs) in human melanoma lesions: Major gateways for
tumor-infiltrating lymphocytes. Oncoimmunology. 2012;1:829–39.
25. Lanca T, Costa MF, Goncalves-Sousa N, Rei M, Grosso AR, Penido C, et al.
Protective role of the inflammatory CCR2/CCL2 chemokine pathway
through recruitment of type 1 cytotoxic gammadelta T lymphocytes to
tumor beds. J Immunol. 2013;190:6673–80.
26. Katoh H, Wang D, Daikoku T, Sun H, Dey SK, Dubois RN. CXCR2-Expressing
Myeloid-Derived Suppressor Cells Are Essential to Promote Colitis-
Associated Tumorigenesis. Cancer Cell. 2013;24:631–44.
27. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific
recruitment of regulatory T cells in ovarian carcinoma fosters immune
privilege and predicts reduced survival. Nat Med. 2004;10:942–9.
28. Zou L, Barnett B, Safah H, Larussa VF, Evdemon-Hogan M, Mottram P, et al.
Bone marrow is a reservoir for CD4 + CD25+ regulatory T cells that traffic
through CXCL12/CXCR4 signals. Cancer Res. 2004;64:8451–5.
29. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE(2)-
induced CXCL12 production and CXCR4 expression controls the
accumulation of human MDSCs in ovarian cancer environment. Cancer Res.
2011;71:7463–70.
30. Obermajer N, Wong JL, Edwards RP, Odunsi K, Moysich K, Kalinski P.
PGE(2)-driven induction and maintenance of cancer-associated myeloid-
derived suppressor cells. Immunol Investig. 2012;41:635–57.
Muthuswamy et al. Journal for ImmunoTherapy of Cancer  (2015) 3:6 Page 10 of 1031. Reis ST, Leite KR, Piovesan LF, Pontes-Junior J, Viana NI, Abe DK, et al.
Increased expression of MMP-9 and IL-8 are correlated with poor prognosis
of Bladder Cancer. BMC Urol. 2012;12:18.
32. Svatek RS, Zhao XR, Morales EE, Jha MK, Tseng TY, Hugen CM, et al.
Sequential Intravesical Mitomycin plus Bacillus Calmette-Guerin for
Non-Muscle-Invasive Urothelial Bladder Carcinoma: Translational and Phase I
Clinical Trial. Clin Cancer Res. 2015;21:303–11.
33. Yamada H, Luo Y, Matsumoto T, O’Donnell MA. A novel expression of
macrophage derived chemokine in human bladder cancer. J Urol.
2005;173:990–5.
34. Nepple KG, Lightfoot AJ, Rosevear HM, O’Donnell MA, Lamm DL. Bacillus
Calmette-Guerin with or without interferon alpha-2b and megadose versus
recommended daily allowance vitamins during induction and maintenance
intravesical treatment of nonmuscle invasive bladder cancer. J Urol.
2010;184:1915–9.
35. Lamm D, Brausi M, O’Donnell MA, Witjes JA. Interferon alfa in the
treatment paradigm for non-muscle-invasive bladder cancer. Urol Oncol.
2014;32:35. e21-30.
36. Watchmaker PB, Berk E, Muthuswamy R, Mailliard RB, Urban JA, Kirkwood
JM, et al. Independent regulation of chemokine responsiveness and
cytolytic function versus CD8+ T cell expansion by dendritic cells.
J Immunol. 2010;184:591–7.
37. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P.
Development of Th1-inducing capacity in myeloid dendritic cells requires
environmental instruction. J Immunol. 2000;164:4507–12.
38. Bisiaux A, Thiounn N, Timsit MO, Eladaoui A, Chang HH, Mapes J, et al.
Molecular analyte profiling of the early events and tissue conditioning
following intravesical bacillus calmette-guerin therapy in patients with
superficial bladder cancer. J Urol. 2009;181:1571–80.
39. Mendez-Samperio P, Alba L, Perez A. Mycobacterium bovis bacillus
Calmette-Guerin (BCG)-induced CXCL8 production is mediated through
PKCalpha-dependent activation of the IKKalphabeta signaling pathway in
epithelial cells. Cell Immunol. 2007;245:111–8.
40. Mendez-Samperio P, Perez A, Rivera L. Mycobacterium bovis Bacillus
Calmette-Guerin (BCG)-induced activation of PI3K/Akt and NF-kB signaling
pathways regulates expression of CXCL10 in epithelial cells. Cell Immunol.
2009;256:12–8.
41. Heldwein KA, Liang MD, Andresen TK, Thomas KE, Marty AM, Cuesta N, et al.
TLR2 and TLR4 serve distinct roles in the host immune response against
Mycobacterium bovis BCG. J Leukoc Biol. 2003;74:277–86.
42. Barbalat R, Lau L, Locksley RM, Barton GM. Toll-like receptor 2 on inflammatory
monocytes induces type I interferon in response to viral but not bacterial
ligands. Nat Immunol. 2009;10:1200–7.
43. Liu YC, Simmons DP, Li X, Abbott DW, Boom WH, Harding CV. TLR2
signaling depletes IRAK1 and inhibits induction of type I IFN by TLR7/9.
J Immunol. 2012;188:1019–26.
44. Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of
mature dendritic cells to interact with regulatory T cells is imprinted during
maturation. Cancer Res. 2008;68:5972–8.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
